Analysis of Delayed Surgery and Clinical Outcomes in Intermediate- and High-risk Papillary Thyroid Cancer

被引:2
|
作者
Zhou, Huijun [1 ]
Wu, Jie [2 ]
Shi, Lei [3 ]
Wang, Yu [1 ]
Liu, Bin [1 ]
机构
[1] Sichuan Univ, West China Hosp, Dept Nucl Med, 37 Guoxue Alley, Chengdu 610041, Sichuan, Peoples R China
[2] Panzhihua Univ, Panzhihua Municipal Cent Hosp, Dept Nucl Med, Panzhihua, Sichuan, Peoples R China
[3] Chengdu Fifth Peoples Hosp, Dept Nucl Med, Chengdu, Sichuan, Peoples R China
来源
基金
中国博士后科学基金;
关键词
PTC; papillary thyroid cancer; timing of surgery; radioactive iodine; I-131; therapy; clinical outcomes; ADULT PATIENTS;
D O I
10.1210/clinem/dgac502
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context The optimal timing to performing thyroid surgery following a diagnosis of papillary thyroid cancer (PTC) has yet to be fully defined. Objective We aimed to examine if a delayed surgery may worsen the clinical outcome of PTC patients with intermediate- to high-risk of recurrence. Methods All consecutive PTC patients with intermediate- to high-risk of recurrence who underwent total thyroidectomy and radioactive iodine (RAI) ablation at 3 tertiary hospitals in southwest China were retrospectively included. Excellent response at 1-year follow-up after initial therapy was defined as no clinical, imaging, or biochemical evidence of PTC. Association of the timing of surgery and excellent response rates. Results The study included 871 patients. The median time interval between PTC diagnosis and surgery was 2 months (range, 1-87 months). Patients were divided according to the timing of surgery, < 6 months (group A, 624/871 [71.6%]), >= 6 to 11 months (group B, 123/871 [14.1%]), or >= 12 months (group C, 124/871 [14.2%]). One year after initial therapy, 64.7%, 71.5%, and 66.1% of patients in groups A, B, and C, respectively, achieved excellent response (P = 0.27). The lack of impact of surgery timing was observed across intermediate- to high-risk classifications and all T stage categories. These findings did not change when we separately analyzed the groups according to RAI dose (intermediate-dose group: <= 3.7 GBq [n = 654], and high-activity group: 5.5 GBq [n = 217]) further subdivided according to the timing of surgery. Conclusion Timing of surgery does not seem to affect short-term disease outcomes in intermediate- to high-risk PTC patients. Further research is necessary to assess the impact of delayed surgery on long-term prognosis.
引用
收藏
页码:3389 / 3397
页数:9
相关论文
共 50 条
  • [41] The influence of stimulated thyroglobulin and lymphocyte subsets before radioiodine therapy on the therapeutic response in patients with intermediate- and high-risk papillary thyroid carcinoma
    Chenghui Lu
    Congcong Wang
    Fengqi Li
    Xinfeng Liu
    Guoqiang Wang
    Jiao Li
    Zenghua Wang
    Na Han
    Yingying Zhang
    Zengmei Si
    Xufu Wang
    Clinical and Experimental Medicine, 2023, 23 : 2193 - 2200
  • [42] The influence of stimulated thyroglobulin and lymphocyte subsets before radioiodine therapy on the therapeutic response in patients with intermediate- and high-risk papillary thyroid carcinoma
    Lu, Chenghui
    Wang, Congcong
    Li, Fengqi
    Liu, Xinfeng
    Wang, Guoqiang
    Li, Jiao
    Wang, Zenghua
    Han, Na
    Zhang, Yingying
    Si, Zengmei
    Wang, Xufu
    CLINICAL AND EXPERIMENTAL MEDICINE, 2023, 23 (06) : 2193 - 2200
  • [43] Thermal Partial Prostate Ablation for Intermediate- and High-risk Prostate Cancer: Con
    Gaffney, Christopher D.
    Ehdaie, Behfar
    EUROPEAN UROLOGY FOCUS, 2023, 9 (04): : 660 - 661
  • [44] Optimal treatment for intermediate- and high-risk, nonmuscle-invasive bladder cancer
    van der Meijden, A. P. M.
    THESCIENTIFICWORLDJOURNAL, 2006, 6 : 2611 - 2616
  • [45] A Pharmacodynamic Study of Rapamycin in Men with Intermediate- to High-Risk Localized Prostate Cancer
    Armstrong, Andrew J.
    Netto, George J.
    Rudek, Michelle A.
    Halabi, Susan
    Wood, David P.
    Creel, Patricia A.
    Mundy, Kelly
    Davis, S. Lindsay
    Wang, Ting
    Albadine, Roula
    Schultz, Luciana
    Partin, Alan W.
    Jimeno, Antonio
    Fedor, Helen
    Febbo, Phillip G.
    George, Daniel J.
    Gurganus, Robin
    De Marzo, Angelo M.
    Carducci, Michael A.
    CLINICAL CANCER RESEARCH, 2010, 16 (11) : 3057 - 3066
  • [46] Overview of Management of Intermediate- and High-Risk Pulmonary Embolism
    Tapson, Victor F.
    Weinberg, Aaron S.
    CRITICAL CARE CLINICS, 2020, 36 (03) : 449 - +
  • [47] Plasma Selenium, Manganese Superoxide Dismutase, and Intermediate- or High-Risk Prostate Cancer
    Chan, June M.
    Oh, William K.
    Xie, Wanling
    Regan, Meredith M.
    Stampfer, Meir J.
    King, Irena B.
    Abe, Miyako
    Kantoff, Philip W.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (22) : 3577 - 3583
  • [48] Development and validation of a lung metastasispredicting Nomogram for intermediate- to high-risk differentiated thyroid carcinoma patients
    Yu, F.
    Wang, J.
    Yang, W.
    Yang, Z.
    Ma, W.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (SUPPL 1) : S667 - S667
  • [49] LAPAROSCOPIC SURGERY FOR LOW, INTERMEDIATE AND HIGH-RISK ENDOMETRIAL CANCER: A RETROSPECTIVE ANALYSIS OF LONG-TERM OUTCOMES
    Vardar, M. A.
    Gulec, U. Kucukgoz
    Guzel, A. B.
    Gumurdulu, D.
    Seydaoglu, G.
    Khatib, G.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 : 216 - 216
  • [50] LAPAROSCOPIC SURGERY FOR LOW, INTERMEDIATE AND HIGH-RISK ENDOMETRIAL CANCER: A RETROSPECTIVE ANALYSIS OF LONG-TERM OUTCOMES
    Vardar, M. A.
    Gulec, U. Kucukgoz
    Guzel, A. B.
    Gumurdulu, D.
    Seydaoglu, G.
    Khatib, G.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 : 1121 - 1121